94 related articles for article (PubMed ID: 15787284)
21. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Apr; 72(1):3-8. PubMed ID: 21216488
[TBL] [Abstract][Full Text] [Related]
22. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
23. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
[TBL] [Abstract][Full Text] [Related]
24. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Smith J
Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
[TBL] [Abstract][Full Text] [Related]
25. Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.
Farina G; Longo F; Martelli O; Pavese I; Mancuso A; Moscetti L; Labianca R; Bertolini A; Cortesi E; Farris A; Fagnani D; Locatelli MC; Valmadre G; Ardizzoia A; Tomirotti M; Rulli E; Garassino MC; Scanni A
Clin Lung Cancer; 2011 Mar; 12(2):138-41. PubMed ID: 21550561
[TBL] [Abstract][Full Text] [Related]
26. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
Gaafar RM; Surmont VF; Scagliotti GV; Van Klaveren RJ; Papamichael D; Welch JJ; Hasan B; Torri V; van Meerbeeck JP;
Eur J Cancer; 2011 Oct; 47(15):2331-40. PubMed ID: 21802939
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic options for elderly patients with advanced non-small cell lung cancer.
Avery EJ; Kessinger A; Ganti AK
Cancer Treat Rev; 2009 Jun; 35(4):340-4. PubMed ID: 19155139
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer.
Masago K; Fujita S; Togashi Y; Kim YH; Hatachi Y; Fukuhara A; Nagai H; Irisa K; Sakamori Y; Mio T; Mishima M
Oncol Rep; 2011 Oct; 26(4):795-803. PubMed ID: 21805046
[TBL] [Abstract][Full Text] [Related]
29. Gefitinib and non-small cell lunt cancer.
Prescrire Int; 2013 Nov; 22(143):261-2. PubMed ID: 24427833
[TBL] [Abstract][Full Text] [Related]
30. [Advances in the molecular target therapy in lung cancer].
Lu S; Yu YF; Li Zi
Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):701-4. PubMed ID: 16438897
[No Abstract] [Full Text] [Related]
31. Gefitinib (Iressa) for advanced non-small cell lung cancer.
Med Lett Drugs Ther; 2002 Sep; 44(1138):77-8. PubMed ID: 12205428
[No Abstract] [Full Text] [Related]
32. [Current status of the study of the mechanism of epidermal growth factor receptor targeting drug therapy and their related markers].
Wang Y; Xu JM; Song ST
Zhonghua Zhong Liu Za Zhi; 2005 Sep; 27(9):573-6. PubMed ID: 16438862
[No Abstract] [Full Text] [Related]
33. Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib.
Donovan JC; Ghazarian DM; Shaw JC
Arch Dermatol; 2008 Nov; 144(11):1524-5. PubMed ID: 19015435
[No Abstract] [Full Text] [Related]
34. Discussion - other lung cancer targets.
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S175. PubMed ID: 18520306
[No Abstract] [Full Text] [Related]
35. [A new medication for lung cancer].
Krankenpfl J; 2005; 43(7-10):227. PubMed ID: 16515296
[No Abstract] [Full Text] [Related]
36. Induction chemotherapy in early-stage non-small-cell lung cancer.
Pisters KM
Curr Oncol Rep; 2003 Jul; 5(4):307-8. PubMed ID: 12781072
[No Abstract] [Full Text] [Related]
37. Overview of clinical trials with epidermal growth factor receptor inhibitors in advanced non-small cell lung cancer.
Thomas M
Semin Oncol Nurs; 2002 Nov; 18(4 Suppl 4):20-7. PubMed ID: 12534150
[TBL] [Abstract][Full Text] [Related]
38. Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer.
Natale RB
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S128-30. PubMed ID: 18520295
[TBL] [Abstract][Full Text] [Related]
39. K-ras as a target for lung cancer therapy.
Adjei AA
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S160-3. PubMed ID: 18520303
[TBL] [Abstract][Full Text] [Related]
40. Cancer medicine hits a target.
Sobel RK
US News World Rep; 2002 Jun; 132(19):54. PubMed ID: 12066454
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
